Community Investing Ideas

Global Weekly Picks

US$7.43
FV
52.0% undervalued intrinsic discount
36.80%
Revenue growth p.a.
3.9k
users have viewed this narrative
16users have liked this narrative
0users have commented on this narrative
74users have followed this narrative
CA$1.81
FV
68.5% undervalued intrinsic discount
7.00%
Revenue growth p.a.
3.9k
users have viewed this narrative
3users have liked this narrative
0users have commented on this narrative
26users have followed this narrative
US$560
45.2% undervalued intrinsic discount
Fair Value
Revenue
10.32% p.a.
Profit Margin
21.57%
Future PE
29.01x
Price in 2036
US$1.33k
US$84.45
12.2% overvalued intrinsic discount
Fair Value
Revenue
7% p.a.
Profit Margin
13%
Future PE
25x
Price in 2029
US$109.85
JP¥1.91k
8.9% undervalued intrinsic discount
Fair Value
Revenue
13% p.a.
Profit Margin
11.6%
Future PE
16.55x
Price in 2031
JP¥2.66k
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
US$100
90.1% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1